ProQR Therapeutics N.V. Stock News

ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas

PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an effort, I see little future here.

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies base

ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a year ago.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas

ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, t

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, N

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

What you need to know about trading penny stocks as the year ends The post New Years Penny Stocks Trading Advice: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

ProQR (NASDAQ: PRQR ) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (NYSE: LLY ). This agreement concerns ProQR's Axiomer RNA editing platform.

Two biotech stocks are in the spotlight today, ProQR Therapeutics NV (NASDAQ:PRQR) and Mirati Therapeutics Inc (NASDAQ:MRTX), with the former attracting plenty of options activity.

Shares of ProQR Therapeutics NV PRQR, +1.85% soared 56.3% in premarket trading on Thursday after the company said it expanded an RNA editing deal with Eli Lilly & Co. Inc. LLY, +2.33% aimed at making

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, to